Cover ImageSALE
市場調查報告書

早洩治療的全球市場:2017年∼2021年

Global Premature Ejaculation Treatment Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 315293
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
早洩治療的全球市場:2017年∼2021年 Global Premature Ejaculation Treatment Market 2017-2021
出版日期: 2017年11月15日 內容資訊: 英文 84 Pages
簡介

關於早洩治療

早洩是男性最常見的性功能不全之一。性行為時射精早於希望,或在插入前或短時間,都會導致性伴侶中的一方或雙方感到痛苦。在大多數情況下,早洩可能起因於個人困擾和焦慮,不過,沒有症狀相關的確切原因。可能影響本人與對象的關係。早洩,是從18歲到59歲的男性最常見的性障礙。有效的治療選項有心理諮詢,投藥,延緩射精的性技術,以及組合性治療。

Technavio的分析師預測,從2017年到2021年的期間,全球早洩治療市場將以8.71%的年複合成長率成長。

本報告提供全球早洩治療市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 市場概要

第5章 早洩:疾病概要

第6章 市場情形

  • 市場概況
  • 波特的五力分析

第7章 開發平台情形

第8章 市場劃分:各給藥途徑

  • 口服給藥途徑
  • 局部給藥途徑

第9章 市場劃分:各藥物等級

  • SSRI
  • PDE5抑制劑
  • 醯胺型局部麻醉劑
  • 其他

第10章 地區情形

  • 地區比較
  • 早洩治療市場:南北美洲
  • 早洩治療市場:歐洲、中東、非洲地區
  • 早洩治療市場:亞太地區
  • 主要的已開發國家
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 藥物的線上零售銷售的成長
  • 對早洩的認識提高
  • 新的治療方法

第14章 供應商情形

  • 競爭模式

第15章 主要供應商分析

  • Absorption Pharmaceuticals
  • Bayer
  • Eli Lilly
  • Regent Pacific Group
  • 其他有力供應商

第16章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR15322

About Premature Ejaculation Treatment

Premature ejaculation is one of the most common sexual dysfunctions occurring in men. Ejaculation happens sooner than desired, either shortly or before penetration, resulting in distress to either one or both partners involved in sexual intercourse. There is no exact cause that can be associated with the condition though mostly, premature ejaculation can be attributed to personal distress and anxiety. It can affect an individual's relationship with his partner. Premature ejaculation is the most common sexual disorder found in men aged between 18 to 59. Some of the effective treatment options available include psychological counseling, medications, sexual techniques that delay ejaculation, or a combination of these treatments.

Technavio's analysts forecast the global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global premature ejaculation treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Premature Ejaculation Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Absorption Pharmaceuticals
  • Bayer
  • Eli Lilly
  • Regent Pacific Group

Other Prominent Vendors

  • Dong-A Pharmaceutical
  • Emcure
  • Futura Medical
  • GlaxoSmithKline
  • NeuroHealing Pharmaceuticals
  • Pfizer

Market driver

  • High use of off-label drugs
  • For a full, detailed list, view our report

Market challenge

  • Alternative treatments
  • For a full, detailed list, view our report

Market trend

  • Growing online retail sales of drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: PREMATURE EJACULATION: DISEASE OVERVIEW

PART 06: MARKET LANDSCAPE

  • Market overview
  • Five forces analysis

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION

  • Oral route of administration
  • Topical route of administration

PART 09: MARKET SEGMENTATION BY DRUG CLASS

  • SSRIs
  • PDE5 inhibitors
  • Amide anesthetics
  • Others

PART 10: REGIONAL LANDSCAPE

  • Regional comparison
  • Premature ejaculation treatment market in Americas
  • Premature ejaculation treatment market in EMEA
  • Premature ejaculation treatment market in APAC
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Growing online retail sales of drugs
  • Increase in awareness of premature ejaculation
  • New treatment methods

PART 14: VENDOR LANDSCAPE

  • Competitive scenario

PART 15: KEY VENDOR ANALYSIS

  • Absorption Pharmaceuticals
  • Bayer
  • Eli Lilly
  • Regent Pacific Group
  • Other prominent vendors

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global premature ejaculation treatment market: Overview
  • Exhibit 02: Facts about premature ejaculation
  • Exhibit 03: Severity levels of premature ejaculation
  • Exhibit 04: Clinical diagnosis of premature ejaculation
  • Exhibit 05: Premature ejaculation classification
  • Exhibit 06: Global premature ejaculation treatment market 2016-2021 ($ millions)
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Pipeline molecules by vendors
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Global premature ejaculation treatment market by route of administration 2016
  • Exhibit 11: Global premature ejaculation treatment market by SSRIs 2016-2021 ($ millions)
  • Exhibit 12: Global premature ejaculation treatment market by PDE5 inhibitors 2016-2021 ($ millions)
  • Exhibit 13: Global premature ejaculation treatment market by amide anesthetics 2016-2021 ($ millions)
  • Exhibit 14: Global premature ejaculation treatment market by others 2016-2021 ($ millions)
  • Exhibit 15: Global premature ejaculation treatment market by region 2016-2021 (% share)
  • Exhibit 16: Regional comparison
  • Exhibit 17: Premature ejaculation treatment market in Americas 2016-2021 ($ millions)
  • Exhibit 18: Premature ejaculation treatment market in Americas - Year over year growth
  • Exhibit 19: Premature ejaculation treatment market in EMEA 2016-2021 ($ millions)
  • Exhibit 20: Premature ejaculation treatment market in EMEA - Year over year growth
  • Exhibit 21: Premature ejaculation treatment market in APAC 2016-2021 ($ millions)
  • Exhibit 22: Premature ejaculation treatment market in APAC - Year over year growth
  • Exhibit 23: Key leading countries
  • Exhibit 24: Pharmacologic efficacy of some SSRIs
  • Exhibit 25: Premature ejaculation treatment drugs and their subsequent side effects
  • Exhibit 26: Factors challenging the treatment of premature ejaculation
  • Exhibit 27: Absorption Pharmaceuticals: Key highlights
  • Exhibit 28: Absorption Pharmaceuticals: Strength assessment
  • Exhibit 29: Absorption Pharmaceuticals: Strategy assessment
  • Exhibit 30: Absorption Pharmaceuticals: Opportunity assessment
  • Exhibit 31: Bayer: Key highlights
  • Exhibit 32: Bayer: Strength assessment
  • Exhibit 33: Bayer: Strategy assessment
  • Exhibit 34: Bayer: Opportunity assessment
  • Exhibit 35: Eli Lilly: Key highlights
  • Exhibit 36: Eli Lilly: Strength assessment
  • Exhibit 37: Eli Lilly: Strategy assessment
  • Exhibit 38: Eli Lilly: Opportunity assessment
  • Exhibit 39: Regent Pacific Group: Key highlights
  • Exhibit 40: Regent Pacific Group: Strength assessment
  • Exhibit 41: Regent Pacific Group: Strategy assessment
  • Exhibit 42: Regent Pacific Group: Opportunity assessment
Back to Top